nach oben

Erschienen in:

01.08.2014 | Original Article

Circulating biomarkers in hepatocellular carcinoma

verfasst von: Karen L. Morris, Jonathan D. Tugwood, Leila Khoja, Matthew Lancashire, Robert Sloane, Debbie Burt, Patrick Shenjere, Cong Zhou, Clare Hodgson, Toshihiko Ohtomo, Atsuhiko Katoh, Takahiro Ishiguro, Juan W. Valle, Caroline Dive

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aims are to determine levels of circulating cellular and protein biomarkers in hepatocellular carcinoma (HCC) patients and to analyse any relationships with clinical parameters.

Methods

Fifty-four consenting patients were recruited. Circulating tumour cells (CTCs) were enumerated (by CellSearch) and characterised via filtration [by isolation by size of epithelial tumour cells (ISET)] with downstream immunohistochemistry (IHC). Glypican-3 (GPC3) expression in tumour biopsies and CTCs (by IHC) was compared, and levels of circulating caspase-cleaved and full-length cytokeratin 18 (CK18, measured using M30 and M65 ELISAs) were examined as a putative prognostic factor and marker of tumour burden.

Results

CTCs were identified in 14 out of 50 (28 %) patients by CellSearch and in 19 out of 19 (100 %) patients by ISET. The presence of GPC3-positive CTCs by ISET was 100 % concordant with the presence of GPC3-positive cells in the original tumour (n = 5). No statistically significant correlations were observed between CTC number and clinical characteristics, although trends were noted between CTC subtypes, Child–Pugh score and tumour node metastasis stage. Serum M30 and M65 levels (as continuous variables) significantly correlated with overall survival (OS) in a univariate analysis (p = 0.003 and p < 0.001, respectively); M65 levels remained statistically significant in a multivariate analysis (p = 0.029).

Conclusions

This is the first study to detect GPC3-positive CTCs in HCC, important for drug development with this target. The significant association of circulating CK18 with OS in HCC further exemplifies the utility of circulating biomarkers in cancer.

Nur mit Berechtigung zugänglich

Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394–399PubMedCrossRef

Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37(5):1202–1219PubMedCrossRef

Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306(1):16–25PubMedCrossRef

Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V (2006) Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 37(11):1435–1441PubMedCrossRef

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA (2013) First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 19(4):920–928PubMedCrossRef

Hou J-M, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall F (2009) Evaluation of circulating tumour cells and serological death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175:808–816PubMedCentralPubMedCrossRef

Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non small-cell lung cancer. J Clin Oncol 29(12):1556–1563PubMedCrossRef

Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P (2000) Isolation by size of epithelial tumour cells: a new method for the immunomorphological and molecular characterisation of circulating tumour cells. Am J Pathol 156:57–63PubMedCentralPubMedCrossRef

Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H (2008) Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68(23):9832–9838PubMedCrossRef

10.

Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M (2009) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378(2):279–284PubMedCrossRef

11.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904PubMedCrossRef

12.

Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13(3):920–928PubMedCrossRef

13.

Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 106(3):508–516PubMedCentralPubMedCrossRef

14.

Cummings J, Ward T, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532–538PubMedCentralPubMed

15.

Cummings J, Ranson M, LaCasse E, Gangangari J, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42–48PubMedCentralPubMedCrossRef

16.

Gao P, Jiao S-C, Bai L, Wang H, Jing F–F, Yang J-L (2013) Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J Int Med Res 41(4):923–933PubMedCrossRef

17.

Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35(1):122–128PubMedCrossRef

18.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136(3):1012–1024PubMedCentralPubMedCrossRef

19.

Sun Y-F, Xu Y, Yang X-R, Guo W, Zhang X, Qiu S-J, Shi R-Y, Hu B, Zhou J, Fan J (2013) Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57(4):1458–1468PubMedCrossRef

20.

Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133(9):1365–1371CrossRef

21.

Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, Bréchot C, Paterlini-Bréchot P (2004) Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3):792–797PubMedCrossRef

22.

Pantel K, Alix-Panabières C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–406PubMedCrossRef

23.

Zhang YLJ, Cao L, Xu W, Zhengfeng Yin (2012) Circulating tumour cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 39:449–460PubMedCrossRef

24.

Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker method validation in anticancer drug development. Br J Pharmacol 153(4):646–656PubMedCentralPubMedCrossRef

25.

Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG (2012) Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer 107(9):1518–1524PubMedCentralPubMedCrossRef

26.

Oyama K, Fushida S, Kinoshita J, Okamoto K, Makino I, Nakamura K, Hayashi H, Inokuchi M, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fujimura T, Ohta T (2012) Serum cytokeratin 18 as a biomarker for gastric cancer. Clin Exp Med 13(4):289–295PubMedCrossRef

27.

Yildiz I, Sen F, Kilic L, Keskin S, Duranyildiz D, Bilgin E, Disci R, Ekenel M, Darendeliler E, Bavbek S, Basaran M (2013) Serum M65 as a biomarker for metastatic renal cell carcinoma. Clin Genitourin Cancer 11(3):290–296PubMedCrossRef

28.

Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiss M, Kronenberger B, Piiper A (2013) Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 59(4):769–779PubMedCrossRef

29.

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A (2010) Major histocompatibility complex class I–related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 51(1):92–102PubMedCrossRef

30.

Maliken B, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV (2013) Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 57(5):1806–1813PubMedCentralPubMedCrossRef

Titel: Circulating biomarkers in hepatocellular carcinoma
verfasst von: Karen L. Morris
Jonathan D. Tugwood
Leila Khoja
Matthew Lancashire
Robert Sloane
Debbie Burt
Patrick Shenjere
Cong Zhou
Clare Hodgson
Toshihiko Ohtomo
Atsuhiko Katoh
Takahiro Ishiguro
Juan W. Valle
Caroline Dive
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2508-7

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Circulating biomarkers in hepatocellular carcinoma